Clinical Trials Logo

Clinical Trial Summary

The new Severe acute respiratory syndrome coronavirus (SARS-CoV-2) named coronavirus disease 2019 (COVID-19) is currently responsible for a pandemic spread of febrile respiratory infections, responsible for a veritable global health crisis. In adults, several evolutionary patterns are observed: i) a/pauci-symptomatic forms; ii) severe forms immediately linked to rare extensive viral pneumonia; and iii) forms of moderate severity, some of which progress to secondary aggravation (Day 7-Day 10). Children can be affected, but are more rarely symptomatic and severe pediatric forms are exceptional. Like some other coronaviruses (SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV)), these differences in clinical expression could be based on a variability in the immunological response, notably either via inhibition of the type I interferon (IFN-I) response, or on the contrary an immunological dysregulation responsible for a "cytokine storm" associated with the aggravation. Little is known about the impact of these innate immune response abnormalities on the adaptive response. In addition, certain genetic factors predisposing to a state of "hyper-fragility" and certain viral virulence factors could also be predictive of the clinical response. In this context, the main hypothesis is that the virological analysis and the initial biological and immunological profiles are correlated with the initial clinical presentation of COVID-19 infection. In particular, children forms and pauci-symptomatic disease in adults may be linked to a more robust innate immune response, including better production of IFN-I.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04376476
Study type Interventional
Source Hospices Civils de Lyon
Contact
Status Completed
Phase N/A
Start date May 5, 2020
Completion date May 13, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05543616 - A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children Phase 2/Phase 3
Recruiting NCT04516811 - Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19 Phase 3
Completed NCT04334044 - Treatment of SARS Caused by COVID-19 With Ruxolitinib Phase 1/Phase 2
Terminated NCT04371978 - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Phase 3
Recruiting NCT04466241 - Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial Phase 2/Phase 3
Withdrawn NCT04381923 - COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia N/A
Recruiting NCT04402879 - CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals N/A
Recruiting NCT04661631 - Surgery and Lung Ultrasound in COVID-19 Infection
Completed NCT04375098 - Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection Phase 2
Completed NCT04402060 - A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 Phase 1/Phase 2
Active, not recruiting NCT04365101 - Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 Phase 1/Phase 2
Completed NCT04354779 - Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.
Recruiting NCT04367207 - African Covid-19 Critical Care Outcomes Study
Terminated NCT04409873 - Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19) Phase 2
Completed NCT04602351 - Communication in ICU During COVID-19
Terminated NCT04707703 - Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis Phase 3
Active, not recruiting NCT04987528 - Pulmonary Fibrosis During Severe COVID-19 Pneumonia
Completed NCT04667936 - Evaluation of Sedation in COVID-19 ARDS
Completed NCT04423770 - COVID-19 Related Health and Infection Control Practices Among Dentists
Completed NCT04379037 - Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients N/A